Does the mechanism of action of lumasiran sodium in primary hyperoxaluria type 1 depend on the specific AGXT gene mutation?

No, the mechanism of action of lumasiran sodium (Oxlumo) in primary hyperoxaluria type 1 is independent of the underlying AGXT gene mutation because it reduces glycolate oxidase, which acts upstream of the deficient alanine:glyoxylate aminotransferase enzyme.